TNON
Tenon Medical, Inc. (TNON) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Liquidity remains tight with a 0.58 current ratio and 0.48 quick ratio, leaving TNON more exposed than better-capitalized peers if demand softens or working capital tightens.
Working-capital intensity is elevated with a 165-day cash conversion cycle, which can constrain growth funding and make TNON less flexible than peers with faster cash generation.
Receivables and inventory are slow-moving at 133 and 159 days outstanding, increasing the risk of cash drag versus peers with tighter collection and stocking discipline.
Negative interest coverage indicates operating earnings are not covering financing costs, so TNON has less margin for error than peers with positive coverage in a higher-rate environment.
Opportunities
If TNON improves collections and inventory turns, the large working-capital release could support liquidity and growth more quickly than peers with already efficient cycles.
Net debt to EBITDA is negative, suggesting leverage is not the primary constraint and TNON may have more balance-sheet flexibility than indebted peers if profitability stabilizes.
The low debt burden relative to EBITDA can help TNON absorb near-term volatility better than leveraged peers, provided operating performance does not deteriorate further.
Overall Score
TNON’s forward positioning is constrained mainly by weak liquidity and heavy working-capital drag, while limited leverage and potential cash-release from efficiency gains provide some offset versus peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Tenon Medical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
